|
| |
Asset
is a fully integrated, uHTS system that can process
a plate every 30 seconds, with one operator using
any assay technology. |
| |
Asset offers a unique
combination of flexibility, assay quality (Z') and
throughput. |
| |
Asset is operational
at major pharmaceutical sites, including GlaxoSmithKline
and AstraZeneca, routinely screening large compound
libraries against a wide range of assay types. |
 |
| |
- Batch sizes in excess of 400 plates with
lids (96, 384 or 1536 well) using PlateSafes
- Reagent addition using temperature controlled
reservoirs with optional gassing and agitation
- Tip washing and drying, in parallel with
pipetting
- Tissue culture quality incubation with CO2
and humidity control
- Finely controlled plate washing for cell-based,
coated-well and ELISA procedures
- Signal detection using multiple readers of
user’s choice
- Complete sample tracking giving full audit
trail
- Unlimited multi-stream transfers between compound,
cell and assay plates within an assay
|
 |
| |
- Processing capacity to handle all likely
workloads - screens 250,000 compounds in 8 hours,
to meet peak demands and complete high priority
screens quickly
- Consistent and reproducible results for even
complex multi-stream uHTS assays - using Asset’s
proprietary plate indexing system
- Flexibility to assemble and measure the full
range of assays – ELISAs, as well as sensitive
cell-based assays
- Rapid and simple changeover between different
assays
- Reliable, unattended operation enables extended-hours
runs
- Choice of user-specified assay technology
and plate readers
|
| |
Asset’s unique
processing style delivers optimised Z’ values
at uHTS throughputs, regardless of assay format.
This enables screening groups to deliver enhanced
service to their clients in therapeutic areas. |
| |
|
